Biosafety and action in front of COVID-19
What do we know?
DOI:
https://doi.org/10.31686/ijier.vol9.iss4.3031Keywords:
Biosafety, SARS-CoV-2, Cross Infection, Health Professionals, COVID-19, Personal Protective Equipment (PPE).Abstract
The COVID-19 disease that affected the entire world in 2020 is caused by a virus (SARS-CoV-2) with a high rate of pathogenicity and transmission that caused several deaths in its trajectory. To combat this disease several personal hygiene measures and the use of personal protective equipment were necessary. In view of this, the study aims to clarify some doubts regarding the vaccine and its effectiveness, individual protection and the performance of health professionals in the face of this situation.
Downloads
References
ABDULLAHI, I. N.; EMERIBE, A. U.; AJAYI, O. A.; ODERINDE, B. S.; AMADU, D. O.; OSUJI, A. I. Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions. Journal of Taibah University Medical Sciences, [s. l.], v. 15, n. 4, p. 258–264, 2020.
AĞALAR, C.; ÖZTÜRK ENGIN, D. Protective measures for covid-19 for healthcare providers and laboratory personnel, 2020.
ALI, K.; RAJA, M. Coronavirus disease 2019 (COVID-19): challenges and management of aerosol-generating procedures in dentistry. Evidence-Based Dentistry, [s. l.], v. 21, n. 2, p. 44–45, 2020.
AMATO, A.; CAGGIANO, M.; AMATO, M.; MOCCIA, G.; CAPUNZO, M.; DE CARO, F. Infection Control in Dental Practice During the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, [s. l.], v. 17, n. 13, p. 4769, 2020.
BAGHIZADEH FINI, M. What dentists need to know about COVID-19, 2020.
BAXTER, D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine, [s. l.], v. 57, n. 8, p. 552–556, 2007.
BHAGAVATHULA, A. S.; RAGHAVAN, V. R.; AHMADI, A.; SRIRAG, D.; CHATTU, V. K. Frontline Healthcare Workers’ Knowledge, Perception and Risk Prevention Practices Regarding COVID-19 in Afghanistan: A Cross-Sectional Study. Medical Sciences, [s. l.], v. 9, n. 1, p. 2, 2021.
BRUM ELIANE, E. B. Pesquisa revela que Bolsonaro executou uma “estratégia institucional de propagação do coronavírus”. EL PAÍS, [s. l.], [s.d.].
CADARI, M. B.; CACHONI, A. C.; TOLEDO NETO, J. L.; JASSI JOSÉ, F.; ZORZI COLÉTE, J.; FOGGIATO, A. A.; DA SILVA, D. F. Biosafety, life and COVID-19: Online questionnaire. International Journal of Advanced Engineering Research and Science, [s. l.], v. 8, n. 1, p. 059–068, 2021.
CORMAN, V. M.; LANDT, O.; KAISER, M.; MOLENKAMP, R.; MEIJER, A.; CHU, D. K. W.; BLEICKER, T.; BRÜNINK, S.; SCHNEIDER, J.; SCHMIDT, M. L.; MULDERS, D. G. J. C.; HAAGMANS, B. L.; VAN DER VEER, B.; VAN DEN BRINK, S.; WIJSMAN, L.; GODERSKI, G.; ROMETTE, J. L.; ELLIS, J.; ZAMBON, M.; PEIRIS, M.; GOOSSENS, H.; REUSKEN, C.; KOOPMANS, M. P. G.; DROSTEN, C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, [s. l.], v. 25, n. 3, p. 1–8, 2020.
COULTHARD, P. Dentistry and coronavirus (COVID-19) - moral decision-making. British Dental Journal, [s. l.], 2020.
DAI, X.; XIONG, Y.; LI, N.; JIAN, C. Vaccine Types. Vaccines - the History and Future, [s. l.], p. 1–9, 2019.
DALKY, H. F.; GHADER, N.; AL KUWARI, M.; ALNAJAR, M.; ISMAILE, S.; ALMALIK, M.; SHUDIFAT, R.; SANAD, S.; AL-NSAIR, N.; AL MATROOSHI, F. Assessment of the Awareness, Perception, Attitudes, and Preparedness of Health-care Professionals Potentially Exposed to COVID-19 in the United Arab Emirates. Journal of Multidisciplinary Healthcare, [s. l.], v. Volume 14, p. 91–102, 2021.
EL-HAGE, W.; HINGRAY, C.; LEMOGNE, C.; YRONDI, A.; BRUNAULT, P.; BIENVENU, T.; ETAIN, B.; PAQUET, C.; GOHIER, B.; BENNABI, D.; BIRMES, P.; SAUVAGET, A.; FAKRA, E.; PRIETO, N.; BULTEAU, S.; VIDAILHET, P.; CAMUS, V.; LEBOYER, M.; KREBS, M.-O.; AOUIZERATE, B. Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks? L’Encéphale, [s. l.], v. 46, n. 3, p. S73–S80, 2020.
GE, Z.; YANG, L.; XIA, J.; FU, X.; ZHANG, Y. Possible aerosol transmission of COVID-19 and special precautions in dentistry. Journal of Zhejiang University-SCIENCE B, [s. l.], v. 21, n. 5, p. 361–368, 2020.
GEORGER, F.; DOS SANTOS, E.; GAZAGNE, L.; BERDAGUÉ, P.; SAIB, A.; NAHON, S.; PIQUET, J.; AMARA, W. COV IMPACT : analyse des différents facteurs de stress du personnel hospitalier dans 2 centres hospitaliers en France lors de la pandémie COVID-19. Annales de Cardiologie et d’Angéiologie, [s. l.], v. 69, n. 5, p. 227–232, 2020.
GURUPRASAD, L. Human SARS CoV-2 spike protein mutations. Proteins: Structure, Function, and Bioinformatics, [s. l.], p. prot.26042, 2021.
HUI, D. S. Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). Clinics in chest medicine, [s. l.], v. 38, n. 1, p. 71–86, 2017.
IZZETTI, R.; NISI, M.; GABRIELE, M.; GRAZIANI, F. COVID-19 Transmission in Dental Practice: Brief Review of Preventive Measures in Italy. Journal of Dental Research, [s. l.], v. 99, n. 9, p. 1030–1038, 2020.
JEAN, S. S.; HSUEH, P. R. Old and re-purposed drugs for the treatment of COVID-19. Expert Review of Anti-Infective Therapy, [s. l.], v. 18, n. 9, p. 843–847, 2020.
JOAQUIM, B. F.; TOLEDO NETO, J. L.; COLÉTE, J. Z.; FOGGIATO, A. A.; SILVA, D. F. Dentistry biosecurity during the SARS-CoV-2 pandemic: what should we know? Joaquim,. [s. l.], p. 1–45, 2020.
KAMPF, G.; TODT, D.; PFAENDER, S.; STEINMANN, E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection, [s. l.], v. 104, n. 3, p. 246–251, 2020.
KLIETZ, M.-L.; KAISER, H. W.; MACHENS, H.-G.; AITZETMÜLLER, M. M. Ac c ep te d Corresponding Author : an us cr ip t Ac c ep te d us cr t. [s. l.], p. 1–31, 2019.
KRAMER, A.; SCHWEBKE, I.; KAMPF, G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infectious Diseases, [s. l.], v. 6, n. 1, p. 130, 2006.
LAIGRET, J. La petite histoire de la découverte de la vaccination contre la fièvre jaune - Jean Laigret (1893-1966). Medecine tropicale : revue du Corps de sante colonial, [s. l.], v. 65, n. 3, p. 290–292, 2005.
LOURENÇO, O. D.; JASSI, F. J.; COLÉTE, J. Z.; FOGGIATO, A. A.; TOLEDO NETO, J. L.; SILVA, D. F. STEM CELLS IN THE TREATMENT OF COVID-19 ACUTE RESPIRATORY SYNDROME: What do we know so far ? [s. l.], v. 10, p. 43079–43083, 2020.
LU, Z. K.; YUAN, J.; LI, M.; SUTTON, S. S.; RAO, G. A.; JACOB, S.; BENNETT, C. L. Cardiac risks associated with antibiotics: Azithromycin and levofloxacin, 2015.
MADEWELL, Z. J.; YANG, Y.; JR, I. M. L.; HALLORAN, M. E.; DEAN, N. E. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1. medRxiv, [s. l.], p. 1–13, 2020.
MAGAGNOLI, J.; NARENDRAN, S.; PEREIRA, F.; CUMMINGS, T.; HARDIN, J. W.; SUTTON, S. S.; AMBATI, J. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv, [s. l.], 2020.
MAHÉVAS, M.; TRAN, V. T.; ROUMIER, M.; CHABROL, A.; PAULE, R.; GUILLAUD, C.; GALLIEN, S.; LEPEULE, R.; SZWEBEL, T. A.; LESCURE, X.; SCHLEMMER, F.; MATIGNON, M.; KHELLAF, M.; CRICKX, E.; TERRIER, B.; MORBIEU, C.; LEGENDRE, P.; DANG, J.; SCHOINDRE, Y.; PAWLOTSKI, J. M.; MICHEL, M.; PERRODEAU, E.; CARLIER, N.; ROCHE, N.; DE LASTOURS, V.; MOUTHON, L.; AUDUREAU, E.; RAVAUD, P.; GODEAU, B.; COSTEDOAT-CHALUMEAU, N. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: Results of a study using routinely collected data to emulate a target trial. medRxiv, [s. l.], p. 1–20, 2020.
MARTIN, C. Tuberculosis vaccines: Past, present and future. Current Opinion in Pulmonary Medicine, [s. l.], v. 12, n. 3, p. 186–191, 2006.
MENG, L.; HUA, F.; BIAN, Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. Journal of Dental Research, [s. l.], v. 99, n. 5, p. 481–487, 2020.
MODELLI, L. 4 vacinas contra a Covid apresentam taxas satisfatórias de eficácia e de segurança; veja comparativo. [s.d.].
MODI, P. D.; NAIR, G.; UPPE, A.; MODI, J.; TUPPEKAR, B.; GHARPURE, A. S.; LANGADE, D. COVID-19 Awareness Among Healthcare Students and Professionals in Mumbai Metropolitan Region: A Questionnaire-Based Survey. Cureus, [s. l.], 2020.
NAGY, Á.; PONGOR, S.; GYŐRFFY, B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. International Journal of Antimicrobial Agents, [s. l.], v. 57, n. 2, p. 106272, 2021.
NUNES, K. Ineficaz contra a Covid-19, ivermectina tem aumento de 615% nas vendas em Pernambuco. Brasil de fato - pernanbuco, [s. l.], [s.d.].
ORTEGA, R.; GONZALEZ, M.; NOZARI, A.; CANELLI, R. Personal Protective Equipment and Covid-19. New England Journal of Medicine, [s. l.], 2020.
OTTER, J. A.; YEZLI, S.; SALKELD, J. A. G.; FRENCH, G. L. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. American Journal of Infection Control, [s. l.], v. 41, n. 5, p. S6–S11, 2013.
PASCARELLA, G.; STRUMIA, A.; PILIEGO, C.; BRUNO, F.; DEL BUONO, R.; COSTA, F.; SCARLATA, S.; AGRÒ, F. E. COVID-19 diagnosis and management: a comprehensive review, 2020.
PASSARINHO, N. A potencial vantagem da CoronaVac contra variantes do coronavírus. [s.d.].
PEELING, R. W.; WEDDERBURN, C. J.; GARCIA, P. J.; BOERAS, D.; FONGWEN, N.; NKENGASONG, J.; SALL, A.; TANURI, A.; HEYMANN, D. L. Serology testing in the COVID-19 pandemic response. The Lancet Infectious Diseases, [s. l.], v. 20, n. 9, p. e245–e249, 2020.
PLOTKIN, S. History of vaccination, 2014.
PLOTKIN, S. A. Vaccines: Past, present and future. Nature Medicine, [s. l.], v. 11, n. 4S, p. S5, 2005.
PLOTKIN, S. A.; GILBERT, P. B. Nomenclature for immune correlates of protection after vaccination. Clinical Infectious Diseases, [s. l.], 2012.
POR G1. Vacinação contra a Covid-19 no Brasil: veja perguntas e respostas. [s. l.], [s.d.].
ROBSON, B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Computers in Biology and Medicine, [s. l.], v. 121, p. 103749, 2020.
ROSENBERG, E. S.; DUFORT, E. M.; UDO, T.; WILBERSCHIED, L. A.; KUMAR, J.; TESORIERO, J.; WEINBERG, P.; KIRKWOOD, J.; MUSE, A.; DEHOVITZ, J.; BLOG, D. S.; HUTTON, B.; HOLTGRAVE, D. R.; ZUCKER, H. A. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. JAMA - Journal of the American Medical Association, [s. l.], 2020.
ROTHAN, H. A.; BYRAREDDY, S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, 2020.
SAKAMOTO, L. S. Ivermectina, como o governo Bolsonaro, não tem eficácia contra a covid-19. [s.d.].
SHEREEN, M. A.; KHAN, S.; KAZMI, A.; BASHIR, N.; SIDDIQUE, R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, [s. l.], v. 24, p. 91–98, 2020.
SILVA, L. B. Covid-19: Cepa de Manaus pode comprometer desenvolvimento de anticorpos, diz OMS. [s.d.]. Disponível em: <https://www.cnnbrasil.com.br/saude/2021/02/10/covid-19-cepa-de-manaus-pode-comprometer-desenvolvimento-de-anticorpos-diz-oms>.
STRUNK, J. L.; TEMESGEN, H.; ANDERSEN, H.; PACKALEN, P. In Pr es s In es. [s. l.], v. 80, n. 2, p. 1–8, 2014.
THANH LE, T.; ANDREADAKIS, Z.; KUMAR, A.; GÓMEZ ROMÁN, R.; TOLLEFSEN, S.; SAVILLE, M.; MAYHEW, S. The COVID-19 vaccine development landscape. Nature reviews. Drug discovery, [s. l.], v. 19, n. 5, p. 305–306, 2020. Disponível em: <http://dx.doi.org/10.1038/d41573-020-00073-5>
WANG, P. W.; LU, W. H.; KO, N. Y.; CHEN, Y. L.; LI, D. J.; CHANG, Y. P.; YEN, C. F. COVID-19-Related Information Sources and the Relationship with Confidence in People Coping with COVID-19: Facebook Survey Study in Taiwan, 2020.
WHO. Rational use of personal protective equipment for coronavirus disease 2019 ( COVID-19 ). World Health Organization, [s. l.], v. 27, n. February, p. 1–7, 2020.
WORLD HEALTH ORGANIZATION. Laboratory biosafety guidance related to coronavirus disease (COVID-19). Interim guidance, [s. l.], n. 19 March, p. 1–5, 2020. a.
WORLD HEALTH ORGANIZATION. Laboratory biosafety guidance related to the novel coronavirus ( 2019-nCoV ). World Health Organisation, [s. l.], n. February, p. 1–12, 2020. b.
WORLD HEALTH ORGANIZATION (WHO). Rational use of personal protective equipment for coronavirus disease 2019 ( COVID-19 ). World Health Organization, [s. l.], 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Anna Clara Cachoni, Micael Borges Cadari, Augusto Alberto Foggiato, Juliana Zorzi Coléte, João Lopes Toledo Neto, Fabrício José Jassi, Douglas Fernandes da Silva
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyrights for articles published in IJIER journals are retained by the authors, with first publication rights granted to the journal. The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author for more visit Copyright & License.
